Late-breaking data from landmark coapt™ trial show long-term benefits of abbott's mitraclip™ device
New five-year data presented at american college of cardiology scientific sessions (acc.23) and simultaneously published in the new england journal of medicine reinforce the long-term safety and effectiveness of mitraclip for treating secondary mitral regurgitation (mr) results show minimally invasive mitral valve repair in advanced heart failure patients reduces hospitalizations and deaths and provides durable reduction in the severity of mr historically, advanced heart failure patients battling secondary mr (a leaky mitral valve caused by problems affecting other areas of the heart) have been challenging to treat as a result of limited therapy options abbott park, ill., march 5, 2023 /prnewswire/ -- abbott (nyse: abt) today announced late-breaking data for mitraclip™, the leading therapy to treat leaky valves in people with mitral regurgitation (mr), that demonstrate long-term benefits of the device in patients battling heart failure.
ABT Ratings Summary
Quant
ABT Quant Ranking
Sector
Industry
Quant Rating
Quant Score
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission